Imuno
Imuno Therapeutics is a biotechnology company based in Leiden, Netherlands, specializing in precision immunotherapy for hard-to-treat diseases such as cancer and autoimmune disorders. The company develops next-generation TCRmimic (TCRm) antibodies targeting intracellular peptide-HLA (pHLA) antigens, which are largely untapped by conventional therapies. Their proprietary Imuno TACTICS™ platform combines structural epitope mapping and advanced paratope prediction to engineer highly specific and potent immunotherapies that minimize cross-reactivity and maximize therapeutic safety and efficacy. Imuno operates as a scale-up with a skilled team leveraging AI and synthetic biology to redefine targeted immunotherapy, focusing on patients with no current treatment options. The company emphasizes innovation, ethical excellence, and patient impact, positioning itself as a leader in the emerging field of intracellular antigen targeting for oncology and autoimmune therapy.
Imuno
Imuno Therapeutics is a biotechnology company based in Leiden, Netherlands, specializing in precision immunotherapy for hard-to-treat diseases such as cancer and autoimmune disorders. The company develops next-generation TCRmimic (TCRm) antibodies targeting intracellular peptide-HLA (pHLA) antigens, which are largely untapped by conventional therapies. Their proprietary Imuno TACTICS™ platform combines structural epitope mapping and advanced paratope prediction to engineer highly specific and potent immunotherapies that minimize cross-reactivity and maximize therapeutic safety and efficacy. Imuno operates as a scale-up with a skilled team leveraging AI and synthetic biology to redefine targeted immunotherapy, focusing on patients with no current treatment options. The company emphasizes innovation, ethical excellence, and patient impact, positioning itself as a leader in the emerging field of intracellular antigen targeting for oncology and autoimmune therapy.